National and Kapodistrian University of Athens
The effect of smoking cessation on metabolic parameters in patients with diabetes mellitus
Abstract
dc:descriptionSmoking cessation is highly recommended as a critical intervention for reducing morbidity and mortality in individuals with diabetes, as smoking exacerbates insulin resistance, impairs glycemic control, and increases the risk of both microvascular and macrovascular complications, especially cardiovascular disease, in people with type 2 diabetes mellitus (T2DM). However, post-smoking-cessation weight gain (PSCWG) may attenuate some of the health benefits and discourage quitting attempts. This weight gain occurs due to the removal of nicotine’s regulatory effects on the central nervous system and its impact on appetite-regulating hormones and peptides. Nicotine increases energy expenditure, resting metabolic rate, and suppresses appetite through interactions with various peptides and hormones that regulate food intake and body weight, such as leptin, resistin, adiponectin, ghrelin, insulin, glucagon-like peptide 1 (GLP-1), and peptide YY (PYY), many of which play crucial roles in the pathophysiology of T2DM. While the cardiovascular benefits of smoking cessation are well-established, PSCWG can temporarily exacerbate diabetes and deteriorate glycemic control. Despite extensive research on PSCWG in the general population, few studies have specifically explored its effects in individuals with T2DM. Varenicline, a partial agonist of α4β2 nicotinic receptors, has similar effects to nicotine and is widely used as a pharmacological intervention for smoking cessation. However, its impact on body weight, appetite regulation, insulin sensitivity, and metabolism in this population remains insufficiently studied. The purpose of this study is to investigate the effects of smoking cessation, aided by varenicline, on a comprehensive set of metabolic parameters in individuals with T2DM and prediabetes. Fifty-three patients were enrolled, of whom 32 successfully quit smoking, following a three-month varenicline course, and were further assessed after an additional month without medication. During the 4 months of the study, participants underwent assessments at three key time points: baseline, 2.5 months into varenicline administration, and 4 months after the beginning of the study. Measurements included body weight, blood pressure, resting metabolic rate (RMR), glycated hemoglobin (HbA1c), fasting glucose, blood lipids, C-reactive protein (CRP), appetite-regulating hormones, and physical activity. At the end of the study, no significant changes were observed in body weight, blood pressure, RMR, or glycemic control. However, significant improvements in lipid profiles were noted: total cholesterol (CHOL) and low-density lipoprotein cholesterol (LDL-C) levels decreased significantly at 4-months of the study (from 168 to 156 mg/dL, p = 0.013 and from 96 to 83 mg/dL, p=0.013, respectively). High-density lipoprotein cholesterol (HDL-C) levels increased significantly at 2.5 months (from 44 to 45 mg/dL, p = 0.042), but this effect was not sustained at 4 months. Triglyceride (TG) levels showed a downward trend, but the reductions were not statistically significant. A significant increase in plasma leptin (from 11 to 13.8 ng/dL, p = 0.004) and GLP-1 levels (from 39.6 to 45.8 pM, p = 0.016) was observed at the 4-month follow-up. No significant changes were detected in resistin, adiponectin, ghrelin, insulin, PYY, or HOMA-IR throughout the study period. Correlations between changes in peptide levels and weight-related parameters aligned with findings already reported in the existing literature. Additionally, self-reported level of physical activity intensity improved by the end of the program, as the percentage of participants who reported moderate-intensity activity increased from 28% to 56%, while those reporting high-intensity activity increased from 19% to 22% respectively (p=0.039). In conclusion, our study showed that smoking cessation with varenicline in smokers with T2DM and prediabetes led to significant improvements in lipid profiles, significant increases in plasma leptin and GLP-1 levels, and enhanced physical activity, without significant weight gain or worsening glycemic control. These findings suggest that smoking cessation without adverse metabolic consequences is feasible for diabetic smokers, with additional benefits for lipid metabolism, GLP-1 regulation, and physical activity levels.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Driva, Stamatina
- Δρίβα, Σταματίνα
Subjects
dc:subject × 26- Διακοπή καπνίσματος
- Διαβήτης (σακχαρώδης)
- Νικοτίνη
- Λεπτίνη
- Ρεζιστίνη
- Αδιπονεκτίνη
- GLP-1
- Γκρελίνη
- Σωματικό βάρος
- Λιπιδαιμικό προφίλ
- Smoking cessation
- Diabetes mellitus
- Nicotine
- Leptin
- Resistin
- Adiponectin
- Glucagon like peptide - 1 (GLP-1)
- Ghrelin
- Body weight
- Lipid profile
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58989